Remdesivir News and Research

RSS

Excluding children from COVID-19 clinical trials may limit their treatment options

A new viewpoint article from Harvard Medical School, published in the journal JAMA Pediatrics, discusses the hesitancy to include children in coronavirus disease 2019 (COVID-19) clinical trials, potentially diminishing their therapeutic options in the long run.

7 May 2020

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

Now, a researcher at the University of Missouri has found that four antiviral drugs, including remdesivir, a drug originally developed to treat Ebola, are effective in inhibiting the replication of the coronavirus causing COVID-19.

4 May 2020

Study reports cryo-EM structure of Remdesivir-bound RNA replicase complex from SARS-CoV-2

A team of Chinese scientists have reported the high-resolution cryo-EM structure of Remdesivir-bound RNA replicase complex from SARS-CoV-2, the infective virus of COVID-19.

3 May 2020

KHN’s ‘What the Health?’: SCOTUS decides an ACA case. No, not that case.

The Supreme Court this week rejected the efforts of a Republican-controlled Congress in 2014 to cut off funding to insurance companies under a provision of the Affordable Care Act.

30 Apr 2020

As coronavirus strikes, crucial data in electronic health records hard to harvest

When President Donald Trump started touting hydroxychloroquine as "one of the biggest game changers” for treating COVID-19, researchers hoped electronic health records could quickly tell them if he was on the right track.

30 Apr 2020

Temple University Hospital is offering COVID-19 clinical trials, investigational treatments options

Temple University Hospital is now participating in a variety of clinical trials that are testing investigational treatment options for patients diagnosed with the novel coronavirus, or COVID-19.

30 Apr 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

GlobalData offers view on Gilead’s suspension of Covid-19 trials in China

Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus have been suspended due to lack of eligible patients;

From Gilead Sciences, Inc. 29 Apr 2020

UAB to join international effort to test drugs for COVID-19

The University of Alabama at Birmingham will join an international effort coordinated by Scripps Research to test drugs for COVID-19.

24 Apr 2020

Research looks at best ways to tackle coronavirus crisis

A new study published in the journal Frontiers in Microbiology in April 2020 discusses the most attractive approaches among the broad spectrum of experimental and theoretical strategies being worked on to counter the COVID-19 pandemic.

24 Apr 2020

Scripps Research established international network to find antiviral compounds against COVID-19

With the COVID-19 pandemic continuing to spread around the globe, Scripps Research has quickly established an international network of collaborating scientific laboratories to leverage ReFRAME, the world's leading drug repurposing collection, to find antiviral compounds against the novel coronavirus.

22 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

A promising antiviral drug to fight COVID-19 pandemic

COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. The trial's criteria allows for the treatment of patients early in their clinical course and, in some cases, at times where they might have otherwise been intubated.

17 Apr 2020

Scripps Research establishes collaborative global effort to rapidly find drugs against COVID-19

With the COVID-19 pandemic continuing to spread across the globe, Scripps Research has quickly established an international network of collaborating scientific laboratories to leverage ReFRAME, the world's leading drug repurposing collection, to find antiviral compounds against the novel coronavirus.

16 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

Ebola drug effective against key enzyme of coronavirus that causes COVID-19

Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.

13 Apr 2020

Cost of ‘repurposing’ existing drugs to treat COVID-19

The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.

13 Apr 2020

Remdesivir shows promise in post-infection treatment for COVID-19 disease

The coronavirus disease (COVID-19) has no approved treatment or vaccine as the world grapple with its wrath. The viral infection has so far infected 1.8 million and killed more than 114,000 people. Now, a team of scientists has shown that an experimental antiviral drug, remdesivir, has shown promise in treating patients with severe COVID-19.

13 Apr 2020

Ebola drug now being tested against COVID-19

As the coronavirus pandemic claims lives and overwhelms health care systems throughout the world, scientists are closely watching several late-stage trials of the antiviral drug remdesivir.

8 Apr 2020

Remdesivir News and Research

Excluding children from COVID-19 clinical trials may limit their treatment options

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

Study reports cryo-EM structure of Remdesivir-bound RNA replicase complex from SARS-CoV-2

KHN’s ‘What the Health?’: SCOTUS decides an ACA case. No, not that case.

As coronavirus strikes, crucial data in electronic health records hard to harvest

Temple University Hospital is offering COVID-19 clinical trials, investigational treatments options

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

GlobalData offers view on Gilead’s suspension of Covid-19 trials in China

UAB to join international effort to test drugs for COVID-19

Research looks at best ways to tackle coronavirus crisis

Scripps Research established international network to find antiviral compounds against COVID-19

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A promising antiviral drug to fight COVID-19 pandemic

Scripps Research establishes collaborative global effort to rapidly find drugs against COVID-19

Remdesivir drug stops novel coronavirus from replicating

Ebola drug effective against key enzyme of coronavirus that causes COVID-19

Cost of ‘repurposing’ existing drugs to treat COVID-19

Remdesivir shows promise in post-infection treatment for COVID-19 disease

Ebola drug now being tested against COVID-19

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News